Wegovy Gets Cheaper! Novo Nordisk Takes on Eli Lilly as Obesity Drug Battle Heats Up
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
· 1d · on MSN
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision filed late Wednesday,
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie and Eli Lilly strike mid-sized deals in obesity and molecular glues, priority review vouchers set to take a hit and immuno-oncology matures.
Eli Lilly is partnering with Imagine Entertainment and MACRO to drive industry-wide change and guide in authentically representing disease.
Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical ... In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback